Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...

Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary ...

The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Feb. 25, 2025 — A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram ... High BP May Develop at Different Ages and Paces in East and ...